Q1 Earnings Estimate for JAZZ Issued By HC Wainwright

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Jazz Pharmaceuticals in a research report issued on Monday, March 10th. HC Wainwright analyst O. Livnat expects that the specialty pharmaceutical company will post earnings of $3.45 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $217.00 target price on the stock. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. HC Wainwright also issued estimates for Jazz Pharmaceuticals’ Q2 2025 earnings at $5.47 EPS, Q3 2025 earnings at $5.64 EPS and Q4 2025 earnings at $6.20 EPS.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley reissued an “overweight” rating and issued a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Royal Bank of Canada dropped their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Piper Sandler reissued an “overweight” rating and set a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Finally, UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $145.00 to $179.00 in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $190.53.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $137.96 on Thursday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The business’s 50 day moving average is $129.52 and its two-hundred day moving average is $120.76. The stock has a market capitalization of $8.38 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $148.06.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,736 shares of company stock valued at $4,022,825. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Fuller & Thaler Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals by 117.4% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after purchasing an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth about $59,668,000. Dimensional Fund Advisors LP raised its holdings in shares of Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after buying an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock worth $225,076,000 after purchasing an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp raised its stake in shares of Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after acquiring an additional 296,800 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.